# Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)

> **NCT04033068** · PHASE1 · COMPLETED · sponsor: **Themis Bioscience GmbH** · enrollment: 48 (actual)

## Conditions studied

- Zika Virus Infection

## Interventions

- **BIOLOGICAL:** Two MV-ZIKA-RSP vaccinations (high dose)
- **BIOLOGICAL:** Two MV-ZIKA-RSP vaccination (low dose)
- **BIOLOGICAL:** One MV-ZIKA-RSP vaccination (high dose) and one placebo
- **OTHER:** Two placebo injection

## Key facts

- **NCT ID:** NCT04033068
- **Lead sponsor:** Themis Bioscience GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-02
- **Primary completion:** 2020-01-30
- **Final completion:** 2020-06-10
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04033068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04033068, "Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04033068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*